NRAS Q61L

CI-VAR-00003569Explore in graph →NP_002515.1:p.Gln61LeuNM_002524.4:c.182A>TClinVar 375874 CIViC 95 rs11554290

Curated evidence

Evidence by cancer (11 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–11 of 11 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
NRAS Q61L	Selumetinib + TrametinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	submitted	EID3018 Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC) PMID 23515407 · Ohashi et al., 2013 · Open in CIViC	civic
Malignant Colorectal Neoplasm5
NRAS Q61L	Cetuximab + IrinotecanCombination	Predictive	C	Supports Resistance	3	accepted	EID2181 Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PI…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375874	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	RASopathy; Colorectal cancer; Neuroblastoma; Embryonal rhabdomyosarcoma	germline/somatic	3	Feb 24, 2024	clinvar

Melanoma4
NRAS Q61L	Pan-RAF/MEK Molecular Glue NST-628	Predictive	D	Supports Sensitivity Response	4	submitted	EID13154 In the NRAS Q61L-mutant IPC-298 melanoma model, NST-628 inhibited cell viability and induced apoptosis in vitro. In IPC-298 xenografts, NST-628 at 5 mg/kg once daily or 1.5 mg/kg twice daily produced … (full text at CIViC) PMID 38588399 · Ryan et al., 2024 · Open in CIViC	civic
NRAS Q61L	Temozolomide	Predictive	C	Supports Sensitivity Response	2	accepted	EID22 In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months. PMID 21576590 · Soon et al., 2011 · Open in CIViC	civic
NRAS Q61L	Vemurafenib	Predictive	C	Supports Resistance	—	submitted	EID3825 In a retrospective study of 44 malignant melanoma patients, NRAS Q61L was associated with acquired resistance to vemurafenib monotherapy in one patient with disease progressive tumors harboring NRAS Q… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
NRAS Q61L	Vemurafenib	Predictive	D	Supports Resistance	—	submitted	EID3826 In an in vitro study, the YULOVY and YUFULO cell lines expressing NRAS Q61L were associated with reduced sensitivity to vemurafenib (PLX4032) treatment, as compared to cells expressing wild-type BRAF.… (full text at CIViC) PMID 20149136 · Halaban et al., 2010 · Open in CIViC	civic

Mucosal Melanoma1
NRAS Q61L	Belvarafenib	Predictive	C	Supports Sensitivity Response	2	accepted	EID13215 A patient with mucosal melanoma harboring NRAS Q61L received belvarafenib monotherapy after five prior lines of systemic therapy and achieved a confirmed partial response by RECIST. The patient receiv… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic